Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 76.98
NBIX's Cash to Debt is ranked higher than
86% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. NBIX: 76.98 )
NBIX' s 10-Year Cash to Debt Range
Min: 1.72   Max: No Debt
Current: 76.98

Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
98% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. NBIX: No Debt )
NBIX' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 2
Z-Score: 28.87
M-Score: -7.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3802.12
NBIX's Operating margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. NBIX: -3802.12 )
NBIX' s 10-Year Operating margin (%) Range
Min: -17340.03   Max: 43.82
Current: -3802.12

-17340.03
43.82
Net-margin (%) -3546.26
NBIX's Net-margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. NBIX: -3546.26 )
NBIX' s 10-Year Net-margin (%) Range
Min: -16936.19   Max: 48.53
Current: -3546.26

-16936.19
48.53
ROE (%) -27.01
NBIX's ROE (%) is ranked higher than
54% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. NBIX: -27.01 )
NBIX' s 10-Year ROE (%) Range
Min: -250.63   Max: 94.61
Current: -27.01

-250.63
94.61
ROA (%) -22.95
NBIX's ROA (%) is ranked higher than
53% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. NBIX: -22.95 )
NBIX' s 10-Year ROA (%) Range
Min: -62.22   Max: 26.57
Current: -22.95

-62.22
26.57
ROC (Joel Greenblatt) (%) -2819.04
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. NBIX: -2819.04 )
NBIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2323.57   Max: 2175.88
Current: -2819.04

-2323.57
2175.88
Revenue Growth (3Y)(%) -60.10
NBIX's Revenue Growth (3Y)(%) is ranked lower than
51% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. NBIX: -60.10 )
NBIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -76.6   Max: 175.9
Current: -60.1

-76.6
175.9
EBITDA Growth (3Y)(%) 47.00
NBIX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NBIX: 47.00 )
NBIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.4   Max: 111.1
Current: 47

-64.4
111.1
EPS Growth (3Y)(%) 66.30
NBIX's EPS Growth (3Y)(%) is ranked higher than
96% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. NBIX: 66.30 )
NBIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.8   Max: 66.3
Current: 66.3

-69.8
66.3
» NBIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NBIX Guru Trades in Q4 2013

Pioneer Investments 524,523 sh (+10.55%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2014

NBIX Guru Trades in Q1 2014

Pioneer Investments 434,514 sh (-17.16%)
» More
Q2 2014

NBIX Guru Trades in Q2 2014

Pioneer Investments 511,617 sh (+17.74%)
» More
Q3 2014

NBIX Guru Trades in Q3 2014

Pioneer Investments 503,938 sh (-1.5%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 Sold Out 0.03%$10.6 - $16.7 $ 24.4978%0
George Soros 2013-06-30 New Buy0.03%$10.9 - $13.57 $ 24.4999%200000
Joel Greenblatt 2012-12-31 Sold Out 0.13%$6.88 - $8.66 $ 24.49222%0
Joel Greenblatt 2012-06-30 Add 23.8%0.03%$6.31 - $8.06 $ 24.49241%259903
George Soros 2012-06-30 Sold Out 0.02%$6.31 - $8.06 $ 24.49241%0
Joel Greenblatt 2012-03-31 New Buy0.15%$7.33 - $9.79 $ 24.49208%209930
George Soros 2012-03-31 New Buy0.02%$7.33 - $9.79 $ 24.49208%150000
George Soros 2011-12-31 Sold Out 0.0018%$5.5 - $8.58 $ 24.49262%0
George Soros 2011-09-30 Reduce -23.93%$5.59 - $8.44 $ 24.49265%17800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.30
NBIX's P/B is ranked higher than
55% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. NBIX: 8.30 )
NBIX' s 10-Year P/B Range
Min: 0.9   Max: 108
Current: 8.3

0.9
108
P/S 2449.00
NBIX's P/S is ranked higher than
51% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. NBIX: 2449.00 )
NBIX' s 10-Year P/S Range
Min: 3.15   Max: 2449
Current: 2449

3.15
2449
EV-to-EBIT -30.36
NBIX's EV-to-EBIT is ranked lower than
52% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. NBIX: -30.36 )
NBIX' s 10-Year EV-to-EBIT Range
Min: -165.7   Max: 426.3
Current: -30.36

-165.7
426.3
Current Ratio 13.09
NBIX's Current Ratio is ranked higher than
96% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. NBIX: 13.09 )
NBIX' s 10-Year Current Ratio Range
Min: 1.63   Max: 24.56
Current: 13.09

1.63
24.56
Quick Ratio 13.09
NBIX's Quick Ratio is ranked higher than
96% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. NBIX: 13.09 )
NBIX' s 10-Year Quick Ratio Range
Min: 1.63   Max: 24.56
Current: 13.09

1.63
24.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.76
NBIX's Price/Net Cash is ranked higher than
91% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NBIX: 12.76 )
NBIX' s 10-Year Price/Net Cash Range
Min: 2.62   Max: 254.67
Current: 12.76

2.62
254.67
Price/Net Current Asset Value 12.76
NBIX's Price/Net Current Asset Value is ranked higher than
85% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NBIX: 12.76 )
NBIX' s 10-Year Price/Net Current Asset Value Range
Min: 2.56   Max: 103.76
Current: 12.76

2.56
103.76
Price/Tangible Book 8.31
NBIX's Price/Tangible Book is ranked higher than
63% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. NBIX: 8.31 )
NBIX' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 101.67
Current: 8.31

1.11
101.67
Price/DCF (Projected) 64.45
NBIX's Price/DCF (Projected) is ranked higher than
72% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. NBIX: 64.45 )
NBIX' s 10-Year Price/DCF (Projected) Range
Min: 9.63   Max: 55.55
Current: 64.45

9.63
55.55
Price/Median PS Value 122.45
NBIX's Price/Median PS Value is ranked higher than
53% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. NBIX: 122.45 )
NBIX' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 80.35
Current: 122.45

0.19
80.35
Earnings Yield (Greenblatt) -3.30
NBIX's Earnings Yield (Greenblatt) is ranked higher than
57% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. NBIX: -3.30 )
NBIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 3683.9
Current: -3.3

0.2
3683.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences, Inc., a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

More From Other Websites
ASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial Dec 17 2014
Neurocrine draws bearish trade Dec 11 2014
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline Dec 10 2014
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 04 2014
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 04 2014
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare... Nov 25 2014
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare... Nov 25 2014
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference Nov 12 2014
NEUROCRINE BIOSCIENCES INC Financials Nov 11 2014
10-Q for Neurocrine Biosciences, Inc. Nov 06 2014
NEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report Nov 04 2014
2015 Packed With Catalysts For Neurocrine Bio Nov 04 2014
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer Nov 04 2014
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer Nov 04 2014
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference Nov 03 2014
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference Nov 03 2014
Neurocrine meets 3Q profit forecasts Nov 03 2014
Neurocrine meets 3Q profit forecasts Nov 03 2014
Neurocrine Biosciences Reports Third Quarter 2014 Results Nov 03 2014
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK